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Immune-checkpoint inhibitors represent the new standard of care in patients with advanced NSCLC who progressed after first-
line treatment. This work aim to assess any difference in both efficacy and safety profiles among Nivolumab, Pembrolizumab
and Atezolizumab in pre-treated NSCLC patients. Randomized clinical trials comparing immune-checkpoint inhibitor versus
docetaxel in pre-treated patients with advanced NSCLC were included and direct comparison meta-analysis of selected trials
have been performed. Subsequently the summary estimates of Nivolumab, Pembrolizumab and Atezolizumab emerging from
the direct meta-analysis were selected to provide the pooled estimates of hazard ratio (HR) and relative risk (RR) for the indi-
rect comparisons among these agents. A total of 5 studies met the selection criteria and were included in the meta-analysis.
Indirect comparisons for efficacy outcomes showed the RR for ORR nivolumab versus atezolizumab 1.66 (95% CI 1.0722.58),
pembrolizumab versus atezolizumab 1.94 (95% CI 1.3022.90). No significant differences in both PFS and OS have been
observed. Indirect comparisons for safety showed the RR for G3-5 AEs nivolumab versus pembrolizumab 0.41 (95% CI
0.2920.60), nivolumab versus atezolizumab 0.50 (95% CI 0.3520.72). No significant differences in both pneumonitis and dis-
continuation rate have been observed. The results of this work revealed that nivolumab and pembrolizumab are associated
with a significant increase of ORR as compared to atezolizumab and nivolumab is associated with a significant lower inci-
dence of G3-5 AEs as compared to the other drugs. These evidences could support the oncologists to select the best drug
for each patient.
The advent of immunotherapy has represented one of the
most important innovations in the treatment of lung cancer
over the last decades. Differently from other treatment strate-
gies, modulating the immune system offers the potential for
long-term survival outcomes with a very tolerable safety pro-
ﬁle. Both anti-programmed death-1 (PD1)/programmed
death ligand-1 (PDL1) monoclonal antibodies (MoAbs) dem-
onstrated promising anti-tumor activity in early Phase I tri-
als, leading to about 20% of objective response rates (ORR)
in pre-treated and unselected NSCLC patients.1–3 These
encouraging data have subsequently led to the design of four
Phase III randomized trials comparing single agent immune-
checkpoint inhibitor (ICI) versus standard chemotherapy in
second-line setting, whose ﬁnal results have recently revolu-
tioned the treatment paradigm of lung cancer. Particularly
the CheckMate 017 and 057 studies demonstrated a signiﬁ-
cant overall survival (OS) beneﬁt in favor of the anti-PD1
MoAb nivolumab over docetaxel in pre-treated NSCLC
patients with squamous and non-squamous histology, respec-
tively.4,5 Similarly in the KEYNOTE-010 study the anti-PD1
MoAb pembrolizumab signiﬁcantly improved OS compared
to docetaxel as second-line treatment in patients with PDL1-
positive NSCLC.6 Finally the anti-PDL1 Atezolizumab has
shown a signiﬁcant superiority over docetaxel in the Phase
III OAK trial including NSCLC patients who failed prior
platinum-based chemotherapy,7 conﬁrming the efﬁcacy data
previously emerged from the randomized Phase II POPLAR
study.8 As regards the toxicity, all the ICIs have shown a
very tolerable safety proﬁle, with a signiﬁcant lower incidence
of any grade and severe toxicities as compared with the stan-
dard chemotherapy. However the inhibition of the PD1-axis
has been associated with new emerging autoimmune-
toxicities, including also the development of severe pneumo-
nitis which have led to treatment-related deaths in clinical
trials.4–7 Overall, the results of all these studies convincingly
and consistently demonstrated that PD1/PDL1 inhibitors are
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more effective and better tolerated than the second-line single
agent chemotherapy, thus representing the new standard of
care for NSCLC patients who experienced progression after
platinum combinations.9 To date we have two anti-PD1
MoAbs, nivolumab and pembrolizumab, and one anti-PDL1
MoAb, atezolizumab, approved as second and/or further lines
treatment options in patients with advanced NSCLC. Even if
still limited by a lack of standardization of testing methods,
the immune-histochemical (IHC) detection of tumor PDL1
expression remains the only predictive biomarker approved
for clinical use. Indeed the majority of these studies revealed
that the beneﬁt of anti-PD1/PDL1 inhibitors increased
accordingly with the tumor PDL1-expression.10 However
only pembrolizumab approval was limited to the PDL1-
positive NSCLC, whereas both nivolumab and atezolizumab
may be currently used regardless of tumor PDL1 status.9
Since clinicians have now three different immune-checkpoint
inhibitors with a very similar indication, how might they
chose the best agent for the second-line treatment of NSCLC
patients? In absence of direct comparisons among these ICIs,
it remains crucial identify any differences in both efﬁcacy
and toxicity proﬁles which may help clinicians to select the
best drug for each patient. Therefore, we performed a sys-
tematic review and meta-analysis of all Phase II/III random-
ized clinical trials comparing PD1/PDL1 inhibitors versus
docetaxel in pre-treated NSCLC patients.
Material and Methods
Search strategy
We searched for randomized clinical trials (RCTs) including
patients with histologically proven diagnosis of advanced
NSCLC which compared the immune-checkpoint inhibitors nivo-
lumab, pembrolizumab and atezolizumab with the standard
second-line chemotherapy regimen Docetaxel. We searched
for RCTs using Medline (PubMed), Embase-databases and
Cochrane-Library up to February 2017, with no language restric-
tions. We used the following search terms: “immunotherapy,”
“PD1,” “PDL1,” “nivolumab,” “pembrolizumab,” “atezolizumab,”
“lung cancer,” “non-small cell lung cancer,” “NSCLC”. Relevant
abstracts from the American Society of Clinical Oncology
(ASCO), European Society of Medical Oncology (ESMO), and
World Conference on Lung Cancer (WCLC) were included. We
also explored the ClinicalTrials.gov website (www.clinicaltrials.
gov) to search for unpublished data and ongoing studies.
Selection criteria
According to the aforementioned search clinical trials were
taken into account if they met the following inclusion crite-
ria: (i) patients with histologically proven diagnosis of
NSCLC; (ii) patients who failed prior platinum chemotherapy
regimens (iii) studies comparing single agent anti-PD1/PDL1
MoAb versus docetaxel (iv) studies reporting efﬁcacy out-
comes, including ORR, PFS, OS; (v) studies reporting safety
outcomes, including Grade 3–5 adverse events (G3–G5 AEs),
pneumonitis and discontinuation rate.
We excluded ongoing studies and observational trials in
order to minimize the risk of bias. In case of articles with
multiple follow up over time, we selected those reporting the
most updated data.
Data extraction
Data extraction and assessment was made independently by
two different authors (A.G. and F.P.) and disagreement were
solved by discussion with another author (A.R.). Quality
judgement of selected trials was made following the Cochrane
Handbook for Systematic Reviews of Interventions reported
criteria,11 including: sequence generation, selective outcome
reporting, blinding of participants, personnel and outcome
assessors; incomplete outcome data and allocation conceal-
ment. We deﬁned as “1” a feature at low risk of bias, as “–”
a feature at high risk of bias and as “?” if data were insufﬁ-
cient for a more precise judgement. Two independent
reviewers (A.G, F.P.) evaluated the selective outcome report-
ing bias and disagreements were solved by consensus.
Statistical analysis
The analyzed outcomes for both direct and indirect compari-
sons were OS, PFS, ORR, G3–G5 AEs, pneumonitis and dis-
continuation rate. In addition ORR, PFS and OS were
stratiﬁed according to the tumor PD-L1 expression status.
Since different cut-offs were used to deﬁne PD-L1 positivity
in clinical trials, we selected PD-L1> 1% as reference cut-off
to identify PD-L11 patients in our analysis because it was
recently approved for clinical use in pre-treated NSCLC
patients. As mentioned before, the KEYNOTE-010 trial
enrolled only PD–L11 patients, thus it was not included in
the pooled analysis of PD–L1– patients. We used hazard
ratios (HRs) as measure to assess the association for PFS and
OS (even when stratiﬁed into PD-L1 positive or negative
What’s new?
In advanced non-small cell lung cancer (NSCLC), failure of first-line therapy is followed by the use of immune checkpoint inhib-
itors (ICIs), which have superior survival benefits compared to standard chemotherapy. Three ICIs are available for pre-treated
NSCLC patients: atezolizumab, nivolumab, and pembrolizumab. The present meta-analysis examined differences in efficacy
and safety profiles between these agents. Indirect comparisons of data on clinical outcomes from five studies included in the
meta-analysis reveal significant differences in efficacy and toxicity between atezolizumab and nivolumab and between atezoli-
zumab and pembrolizumab. The findings warrant further investigation given their potential impact on drug selection for NSCLC
patients.
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cohorts, with a 95% conﬁdence interval (CI)). For the other
outcomes (ORR, AE, pneumonitis and discontinuation rate)
we extracted number of events over total patients included in
each arm using Relative Risks (RRs) as measures of associa-
tion. In the ﬁrst phase, we performed three direct comparison
meta-analysis including all selected trials which evaluated
immune-checkpoint inhibitors versus docetaxel (nivolumab vs.
docetaxel, pembrolizumab vs. docetaxel, atezolizumab vs. doce-
taxel). To do this, we calculated the logarithm of HRs
(logHRs) and its standard error for each RCT included in this
analysis. As result, we used the standard meta-analytic tech-
nique to obtain the pooled estimate for all of these compari-
sons.12 Since nivolumab, pembrolizumab and atezolizumab
used the same control arm (docetaxel), subsequently we used
the same meta-analytical technique to perform an indirect
comparison between such three immunotherapeutic agents.
thus we selected the summary estimates of nivolumab, pem-
brolizumab and atezolizumab emerging from the prior meta-
analysis to provide the pooled estimates of HR and OR for the
indirect comparisons of nivolumab versus pembrolizumab,
nivolumab versus atezolizumab and pembrolizumab versus
atezolizumab. These computations were made using the
method described by Glenny and Bucher,13,14 because of its
ability to maintain the randomization advantage of each trial
providing an estimate of the comparisons between treatments.
Considering what above mentioned, if we assumed Nivo/es as
the estimate of the direct comparison between nivolumab ver-
sus docetaxel and pembro/es as the estimate of the direct com-
parison between pembrolizumab and docetaxel, we performed
the indirect comparison of nivolumab versus pembrolizumab
as follow: Nivo/Pembro_indirect (logHR)5 Nivo/es(logHR) –
Pembro/es(logHR). For the variance, the indirect comparison
was computed as follow: Var (log Nivo/Pembro_indir-
ect)5 (Var log Nivo/es)1 (Var log Pembro/es).13–15 Heteroge-
neity between studies was explored using v2 and I-square tests.
We used the random effect-based model by Der Simonian and
Laird to perform meta-analysis if I-square value was higher
than 75% (it was considered as at high risk of heterogeneity).
If not, we used the ﬁxed effect-based Mantel-Haenszel
model.16,17 As regards the risk of bias across studies, we per-
formed a publication bias analysis using Egger’s test providing
the respective Funnel Plot. The meta-analysis was designed
according to the PRISMA—guidelines for reporting of system-
atic reviews.18 We used Cochrane RevMan ver. 5.3 statistical
software to perform the meta-analysis and Comprehensive
Meta – Analysis ver. 2.0 to assess the risk of publication bias
(Egger’s Test). All the p-values were considered as statistically
signiﬁcant if p <0.05.
Results
The search for literature identiﬁed a total of 648 records, of
which 69 were excluded because duplicates; 489 records were
excluded because reviews, letters or commentaries; 72 records
because were non-randomized clinical trials or did not
compare single agent immunotherapy versus chemotherapy
in pre-treated NSCLC patients. A total of ten trials were
assessed for eligibility and ﬁve were excluded because they
were abstracts of subsequent published papers. Finally, a total
of ﬁve studies met all the inclusion/exclusion criteria and
were included in the meta-analysis (Fig. 1). The clinical out-
comes of the included trials are reported in the Tables 1 and 2.
Direct comparisons
Nivolumab versus docetaxel. Two RCTs (Check-Mate017
and Check-Mate057) compared nivolumab versus docetaxel
in a total of 854 patients with advanced NSCLC who pro-
gressed after ﬁrst-line platinum-chemotherapy. Pooled results
showed statistically signiﬁcant differences in favor of nivolu-
mab in terms of both OS (HR 0.68, 95% CI 0.57–0.80;
Supporting Information Fig. S1) and ORR (RR 1.68, 95% CI
1.21–2.34; Supporting Information Fig. S2). Conversely PFS
was not signiﬁcantly different between the two treatments
arms (HR 0.77, 95% CI 0.52–1.13; Supporting Information
Fig. S3). As regard toxicities, nivolumab was associated with
a lower incidence of both G3/G5 AEs (RR 0.17, 95% CI
0.13–0.24) and treatment discontinuation (RR 0.48, 95% CI
0.25–0.94) compared to Docetaxel. Conversely a signiﬁcant
higher risk of pneumonitis was observed in the nivolumab
arm as compared with chemotherapy arm (RR 9.22, 95% CI
1.73–49.10; Supporting Information Fig. S4). Splitting ORR,
PFS and OS according to the tumor PD-L1 expression, we
also noted a signiﬁcant beneﬁt in favor of nivolumab for all
the above mentioned endpoints in the PD–L11 population,
whereas no beneﬁt has been observed in the PD-L1- patients.
Pembrolizumab versus docetaxel. The Phase III KEYNOTE-010
trial randomized a total of 1,034 patients who progressed after
a platinum-based doublet chemotherapy to three treatment
arms including pembrolizumab at two different dosage (2 and
10 mg/kg) and docetaxel. Of note, this study enrolled a selected
PD-L11 population. Pooled results showed that pembrolizu-
mab was signiﬁcantly superior to docetaxel in terms of OS (HR
0.66, 95% CI 0.57–0.77; Supporting Information Fig S1), PFS
(HR 0.83, 95% CI 0.74–0.94; Supporting Information Fig. S3) and
ORR (RR 1.96, 95% CI 1.48–2.59; Supporting Information Fig.
S2). As for nivolumab, pembrolizumab cohort reported a signiﬁ-
cant beneﬁt regarding the risk of G3/G5 AEs (RR 0.41, 95% CI
0.33–0.50) while the incidence of pneumonitis was signiﬁcantly
higher with pembrolizumab as compared to docetaxel arm (RR
2.34, 95% CI 1.21–4.52; Supporting Information Fig. S4).
Atezolizumab versus docetaxel. Atezolizumab is an anti PD-
L1 monoclonal antibody that was compared to docetaxel in a total
of 1137 pre-treated NSCLC patients included in the Phase II POP-
LAR and Phase III OAK studies. As pooled results, we obtained
no signiﬁcant improvements in terms of ORR (RR 1.01, 95% CI
0.76–1.35; Supporting Information Fig. S2) and PFS (HR 0.95,
95% CI 0.83–1.08; Supporting Information Fig. S3), while only OS
resulted signiﬁcantly longer with atezolizumab in the overall pop-
ulation (HR 0.73, 95% CI 0.63–0.85; Supporting Information Fig.
S1). Atezolizumab maintained a signiﬁcant OS beneﬁt regardless
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of tumor PD-L1 expression status. Similarly to the other two
monoclonal antibodies atezolizumab showed also a more tolerable
toxicity proﬁle, with a signiﬁcant lower incidence of G3/G5 AEs
(RR 0.34, 95% CI 0.28–0.41) and discontinuation rate (RR 0.43,
95% CI 0.30–0.62), and an increased risk for pneumonitis (RR
8.77, 95% CI 1.12–68.92; Supporting Information Fig. S4).
Indirect comparisons
We used the meta-analytic technique to perform an indirect com-
parison between nivolumab, pembrolizumab and atezolizumab
pooled results on ORR, PFS, OS (for both PD–L11 and PD–L1–
cohorts if previously reported), G3/G5 AEs, pneumonitis and
discontinuation rate.
Nivolumab versus pembrolizumab. The results of our analy-
sis did not show any signiﬁcant differences in the efﬁcacy
endpoints (ORR, PFS, OS) between these two anti-PD1
inhibitors, even if considering only the PD–L11 population.
Nivolumab was associated with a signiﬁcant reduction of G3/
G5 AEs (RR 0.41, 95% CI 0.29–0.60) together with a not sig-
niﬁcant increment of the risk of pneumonitis (RR 3.94, 95%
CI 0.65–23.79) or discontinuation rate (Fig. 2).
Nivolumab versus atezolizumab. The results of our analysis
revealed a signiﬁcant higher ORR in favor of nivolumab (RR
1.66, 95% CI 1.07–2.58) both in the overall and in the PD–L11
population. No signiﬁcant advantages in favor of nivolumab
Figure 1. Flow-chart of trials selection process.
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were observed for both PFS and OS, except for a not signiﬁcant
trend toward a PFS improvement in the PD-L11 group. Nivo-
lumab was associated with a signiﬁcant lower risk for G3/G5
AEs (RR 0.50, 95% CI 0.35–0.72) and no substantial higher risk
of pneumonitis or discontinuation rate (Fig. 2).
Pembrolizumab versus atezolizumab. The results of our
analysis revealed a signiﬁcant higher ORR in favor of pem-
brolizumab (RR 1.94, 95% CI 1.30–2.90) in the PD–L11
population. As regard AEs, pneumonitis and discontinuation
rate, no signiﬁcant differences have been observed between
Table 2. Outcomes measures stratified according to the tumor PD-L1 expression status or delete the reference as appropriate, maintaining
the numerical order of the references
Study (reference) Drug
ORR
(PD–L11)
n.1
ORR
(PD–L1–)
n.1
PFS (PD–L11)
HR (95% CI)
PFS (PD–L1–)
HR (95% CI)
OS (PD–L11)
HR (95% CI)
OS (PD–L1–)
HR (95% CI)
CheckMate0174 Nivolumab 11/63 9/54 0.67 (0.44–1.01) 0.66 (0.43–1.00) 0.69 (0.45–1.05) 0.58 (0.37–0.92)
Docetaxel 6/56 5/52
CheckMate0575 Nivolumab 38/123 10/108 0.70 (0.53–0.94) 1.19 (0.88–1.61) 0.59 (0.43–0.82) 0.90 (0.66–1.24)
Docetaxel 15/123 15/101
KEYNOTE0106 Pembrolizumab
(2 mg/kg)
62/344 N.A 0.88 (0.74–1.05) N.A 0.71 (0.58–0.88) N.A
Docetaxel 32/343
KEYNOTE0106 Pembrolizumab
(10 mg/kg)
64/346 N.A 0.79 (0.66–0.94) N.A 0.61 (0.49–0.75) N.A
Docetaxel 32/343
POPLAR8 Atezolizumab 26/144 11/144 0.85 (0.63–1.16) 1.12 (0.72–1.77) 0.59 (0.40–0.85) 1.04 (0.62–1.75)
Docetaxel 24/143 14/143
OAK7 Atezolizumab 43/241 14/180 0.91 (0.74–1.12) 1.00 (0.80–1.25) 0.74 (0.58–0.93) 0.75 (0.59–0.96)
Docetaxel 36/222 21/199
1The number of patients reported corresponds to the number of patients evaluable.
Abbreviations: ORR, overall response rate; PFS, progression free survival; OS, overall survival; PD-L1, programmed death-ligand 1; n., number; HR,
hazard ratio; CI, confidence interval; N.A, not available.
Table 1. Clinical outcomes of the trials included in the pooled-analysis
Study
(reference) Drug ORR n.1 PFS HR (95% CI) OS HR (95% CI)
AEs G3–5
n.1
Pneumonitis
n.1
Discontinuation
rate n.1
CheckMate0174 Nivolumab 26/131 0.62 (0.47–0.81) 0.59 (0.44–0.79) 9/131 6/131 6/135
Docetaxel 12/129 71/129 0/129 10/137
CheckMate0575 Nivolumab 56/292 0.92 (0.77–1.1) 0.73 (0.59–0.89) 30/287 8/287 6/292
Docetaxel 36/290 144/268 1/268 15/290
KEYNOTE0106 Pembrolizumab
(2 mg/kg)
62/344 0.88 (0.74–1.05) 0.71 (0.58–0.88) 43/339 16/339 4/345
109/309 6/309 10/343
Docetaxel 32/343
KEYNOTE0106 Pembrolizumab 64/346 0.79 (0.66–0.94) 0.61 (0.49–0.75) 55/343 N.A 6/346
109/309 10/343
(10 mg/kg) Docetaxel 32/343
POPLAR8 Atezolizumab 21/144 0.94 (0.72–1.23) 0.73 (0.53–0.99) 16/144 4/144 11/144
Docetaxel 21/143 52/143 0/144 30/143
OAK7 Atezolizumab 58/425 0.95 (0.82–1.10) 0.73 (0.62–0.87) 90/609 4/609 8/425
Docetaxel 57/425 247/578 0/578 19/425
1The number of patients reported corresponds to the number of patients evaluable.
Abbreviations: ORR, overall response rate; PFS, progression free survival; OS, overall survival; PD-L1, programmed death-ligand 1; n., number; HR,
hazard ratio; CI, confidence interval; N.A, not available.
C
an
ce
r
T
h
er
ap
y
an
d
P
re
ve
n
ti
o
n
Passiglia et al. 1281
Int. J. Cancer: 142, 1277–1284 (2018) VC 2017 UICC
these two compounds, except for a not signiﬁcant trend
toward a higher incidence of G3/G5 AEs (RR 1.21, 95% CI
0.91–1.60) in the atezolizumab arm (Fig. 2).
Risk of bias assessment (QUADAS-2 tool)
Test for publication bias assessment was not reported due to
the small number of studies included in each comparison
(Egger’s test is reliable with at least three studies included in
the analysis). The overall quality of the included studies was
evaluated using the CONSORT checklist statement. In our
analysis, we found a good average quality of all included tri-
als. All trials reported a high risk of performance bias (blind-
ing of participants and personnel) due to the open-label
structure. All trials except KEYNOTE-010 reported an
unclear risk of detection bias because authors did not specify
the role of each researcher in the trial conduction. Finally,
only Check-Mate017 and Check-Mate057 trials of nivolumab
reported an unclear risk of selection bias because authors did
not specify how do they randomize every patient into the
study arms (lack of random sequence and allocation). No sig-
niﬁcant risk detected for attrition and selective reporting
biases (Fig. 3).
Discussion
To date we have three different agents including two PD1 inhibi-
tors nivolumab and Pembrolizumab and one PDL1 inhibitor
atezolizumab approved as standard treatment options for pre-
treated NSCLC patients. On the basis of the results of the
Figure 2. Forest plots for all indirect comparisons among immunecheck-point inhibitors in pre-treated NSCLC patients: nivolumab vs.
pembrolizumab (a); nivolumab vs. atezolizumab (b); pembrolizumab vs. atezolizumab (c).
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CheckMate 0174 and 0575 studies nivolumab received approval
in both squamous and non-squamous histologies, regardless of
tumor PD-L1 expression, while the KEYNOTE-010 trial6 led to
the subsequent approval of pembrolizumab only in patients with
a threshold level of tumor PD-L1 expression >1%. Recently the
clinical world of oncologists was again excited by the ﬁnal results
of the Phase III OAK trial,7 showing that the PD-L1 inhibitor
atezolizumab was superior to docetaxel in previously treated and
unselected patients. In absence of an acute need for another ICI
with a very similar indication, how might these agents distin-
guish themselves as compelling treatment options? Since we will
likely never see direct comparison studies, this work represent an
attempt to indirectly compare these three agents, in order to
identify any potential differences in both activity and toxicity
proﬁles, which could help clinicians in their daily practice. This
meta-analysis included ﬁve randomized studies which compared
PD1/PDL1 inhibitors versus docetaxel in pre-treated NSCLC
patients. The trial design, the setting and the OS as primary out-
come, were the same in all these studies. However, differently
from the studies of nivolumab and atezolizumab, which enrolled
patients not selected for PDL1-status and subsequently stratiﬁed
outcomes according to the tumor PDL1 expression, the
KEYNOTE-010 trial of pembrolizumab included only patients
with a threshold level of tumor PD-L1 expression >1%, thus
producing a potential selection bias. For this reason they were
not included in the pooled analysis of PD–L1– patients, while
were taken into account in the analysis of PD–L11 population.
The results of this work demonstrated a signiﬁcant increase in
ORR with both the anti PD1 MoAb nivolumab and pembrolizu-
mab as compared to the anti-PDL1 atezolizumab in the overall
population and in PDL1-positive patients, while no activity
differences between nivolumab and pembrolizumab have been
observed. None of the three ICIs was statistically superior in
terms of both PFS and OS. However a not signiﬁcant trend
toward a PFS beneﬁt was observed for the anti-PD1 nivolumab
over atezolizumab, particularly in the subgroup of patients with
PDL1-positive tumors. Only KEYNOTE-010 study6 of pembroli-
zumab had an independent radiological review while the radio-
logical evaluation interval differed among the majority of the
studies, thus potentially inﬂuencing the ﬁnal results. However,
the risk of detection bias related to the determination of ORR
endpoint is low, since the assessment of this outcome was consis-
tent and homogeneous across all included studies. A potential
biological explanation of the major activity observed with PD1
inhibitors could be ﬁnd in their ability to simultaneously block
the binding between PD1 receptor and both its natural ligands,
PDL1 and PDL2; while the anti-PDL1 MoAb atezolizumab is
able to block only the PDL1, not inﬂuencing the interaction
between PD1 and PDL2.19 Very interesting are the safety differ-
ences emerging from our indirect comparisons which revealed a
signiﬁcant lower incidence of all Grade 3–5 AEs during nivolu-
mab therapy as compared with both pembrolizumab and atezoli-
zumab treatments. However if we focus on immune-related
toxicities, pembrolizumab has emerged as the best tolerated
agent, since it was associated with the lower incidence of autoim-
mune pneumonitis as compared with the other two checkpoint
inhibitors, even if it is not statistically signiﬁcant. There are some
limitations to the analysis of toxicity data. Indeed, as we men-
tioned before we reported only treatment-related AEs, but it is
obvious that the attribution of an AE as treatment-related could
be somewhat subjective and heterogeneous between clinical trials
and drugs. Another observation is that pembrolizumab-related
AEs were reported for both the two different dosages of 2 mg/kg
and 10 mg/kg investigated in the KEYNOTE-010, and this could
have led to a relative overestimation of the drug-related toxicity,
since the lower dose of 2 mg/kg is currently approved for clinical
use. Finally, the lower incidence of pneumonitis observed with
pembrolizumab should be cautiously interpreted in light of the
toxicity data reported in the different included studies. Indeed
the absence of pneumonitis events described in the chemother-
apy arms of both nivolumab and atezolizumab trials could have
produced an overestimation of pulmonary toxic potential of
both these agents, ultimately inﬂuencing the ﬁnal results of our
analysis. Furthermore no signiﬁcant differences in treatment dis-
continuation rate have been observed among the three approved
immune-checkpoint inhibitors. The majority of oncologists have
long considered the different ICIs targeting PD1 or PDL1 as
equally effective and clinically interchangeable options. However,
despite some limitations, the results of our meta-analysis ﬁrst
revealed some additional differences among these agents, which
Figure 3. Risk of bias of selected trials summary [Color figure can
be viewed at wileyonlinelibrary.com]
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could guide clinicians in their treatment decisions. Particularly
PD1 inhibitors nivolumab and pembrolizumab could be pre-
ferred options for patients with higher tumor burden or symp-
tomatic disease, to whom the decrease of tumor volume
represents a primary objective. Nivolumab seems to be generally
better tolerated than the other two agents. However for patients
with baseline respiratory diseases, which usually have higher risk
to develop autoimmune-pneumonitis, pembrolizumab could be
considered as the preferred option, even if the several above
described limitations regarding safety analysis require further
investigation. The role for immunotherapy in lung cancer is rap-
idly evolving thanks to the advent of new exciting data from ran-
domized trials investigating both anti-PD1 and anti-PDL1
inhibitors in ﬁrst-line setting.20,21 The KEYNOTE-024 study20
ﬁrst compared pembrolizumab versus platinum-doublets che-
motherapy in untreated EGFR/ALK wild-type NSCLC patients
whose tumors expressed high-level (>50%) PD-L1 expression.
The study met its primary endpoint of PFS (HR: 0.50, 95%CI:
0.37–0.68; p< 0.005) favoring pembrolizumab over ﬁrst-line
chemotherapy and leading to a paradigm shift in ﬁrst-line.
Indeed for about 30% of NSCLC patients with tumor PD-L1
>50% the optimal strategy now is starting with Pembrolizumab
as upfront treatment. However for the majority of patients with
lower-level, negative, or unknown PDL1 status who won’t
receive immunotherapy in ﬁrst-line, the PD1 inhibitors
nivolumab and pembrolizumab and the PDL1 inhibitor atezoli-
zumab represent the new standard second-line options. Particu-
larly the use of pembrolizumab is restricted to PDL1-positive
patients, while both nivolumab and atezolizumab have been
approved regardless of tumor PDL1 status.9 Despite the regula-
tory recommendations the majority of studies including pre-
treated NSCLC patients showed that even if the beneﬁt of ICIs
increased accordingly to the tumor PDL1-expression, PDL1 neg-
ative patients also beneﬁted from ICIs,4–7 suggesting that,
because of its low sensibility (72%) and speciﬁcity (58%), PDL1
status alone is not an appropriate biomarker to exclude pre-
treated patients from immunotherapy. Thus, beyond PDL1
expression, how to choose among three different drugs approved
in the same setting? The results of our work revealed some inter-
esting differences in both activity and safety proﬁles among these
ICIs. Considering the limitations and the potential bias related to
indirect comparisons, these evidences should not considered as a
decisional tool to establish the superiority of one drug to another.
However, they could only serve as a scientiﬁc support to help the
oncologists in their clinical decisions in order to select the best
drug for each patient.
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